GRAIL is trading 4.55% up now at $83.21 after a volatile week, with no clear company-specific catalyst identified for August 27, 2026.
- Latest disclosed developments are the August 7 FDA advisory-committee announcement for Galleri and August 5 second-quarter results.
- GRAIL’s investor-relations page lists no newer release through August 27.
- The broader market is risk-on, led by technology stocks, but offers only limited explanation for GRAIL’s move.